Inactive Instrument

Progenics Pharmaceuticals, Inc.

Equities

US7431871067

Biotechnology & Medical Research

Progenics Pharmaceuticals, Inc. Appoints David W. Mims as Interim Chief Financial Officer

April 01, 2020 at 04:46 pm EDT

On March 27, 2020, David W. Mims, 57, was appointed Interim Chief Financial Officer of Progenics Pharmaceuticals, Inc., effective immediately. Mr. Mims will continue to serve as Interim Chief Executive Officer of the company, which position he has held since November 2019.

Latest news about Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.	Feb. 29	CI
Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.	Jan. 08	CI
International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc	20-12-28	CI
Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., and Exini Diagnostics AB Announces U.S. Food and Drug Administration Clearance for Ai-Enabled Automated Bone Scan Index in Prostate Cancer on GE Healthcare’S Xeleris Platform	20-11-13	CI
Progenics Pharmaceuticals, Inc. Announces Board Changes	20-06-22	CI
Progenics Pharmaceuticals, Inc. Announces Executive Changes	20-06-22	CI
Progenics Pharmaceuticals, Inc. Announces Executive Changes	20-06-22	CI
Progenics Pharmaceuticals, Inc. Appoints Robert J. Marshall Jr. as Treasurer	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P Composite 1500	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P 600	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P 1000	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P TMI Index	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P Global BMI Index	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P 600 Health Care	20-06-22	CI
Progenics Pharmaceuticals, Inc.(NasdaqGS:PGNX) dropped from S&P Biotechnology Select Industry Index	20-06-22	CI
Lantheus Holdings, Inc. completed the acquisition of Progenics Pharmaceuticals, Inc. from Velan Capital, L.P., Virinder Nohria, LTE Partners, LLC, Terence Cooke, Gérard Ber and others.	20-06-18	CI
Progenics Pharmaceuticals, Inc. Announces Results from the Phase 3 Condor Trial of Pyl™	20-05-18	CI
Transcript : Progenics Pharmaceuticals, Inc., Q1 2020 Earnings Call, May 07, 2020	20-05-07
Progenics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-07	CI
Velan Capital Enters into Letter Agreement with Progenics Pharmaceuticals	20-04-15	CI
Velan Capital Agrees to Support Merger of Lantheus and Progenics	20-04-14	CI
Progenics Pharmaceuticals, Inc. Appoints David W. Mims as Interim Chief Financial Officer	20-04-01	CI
Progenics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2019	20-03-13	CI
Progenics Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	20-03-12	CI
Patrick Fabbio Intends to Resign as Progenics Pharmaceuticals's Chief Financial Officer	20-03-04	CI

Chart Progenics Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs